Garcimangosone A

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Garcimangosone A
• 英文别名: 11,22-dihydroxy-7,7,18,18-tetramethyl-15-(3-methylbut-2-enyl)-2,6,17-trioxapentacyclo[12.8.0.03,12.05,10.016,21]docosa-1(14),3,5(10),8,11,15,19,21-octaen-13-one
• 化学式: C₂₈H₂₈O₆
• 分子量: 460.5
• InChiKey: SSITWAPGVBPANU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3502130A1

  公开（公告）日：2019-06-26

  Disclosed is a ligand regulated protein-protein interaction system based on a lipocalin-fold molecule comprising: (a) a lipocalin-fold molecule (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below, and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand, and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 µM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

  所公开的是一种基于脂钙蛋白折叠分子的配体调节蛋白质-蛋白质相互作用系统，该系统包括 (a) 脂钙蛋白折叠分子 (b) 低分子量为 1500 Da 或以下的脂钙蛋白-折叠配体，以及 (c) 脂钙蛋白-折叠结合相互作用伙伴、 其中脂钙素折叠分子可与脂钙素折叠配体结合；以及 其中与脂钙蛋白配体结合的脂钙蛋白-折叠分子与脂钙蛋白-折叠结合相互作用伙伴结合的亲和力比未与脂钙蛋白-折叠配体结合的脂钙蛋白-折叠分子的亲和力至少高 10 倍、 其中脂钙蛋白-折叠结合相互作用伙伴不是天然存在的蛋白质，它在任何脂钙蛋白-折叠配体存在下对任何天然存在的脂钙蛋白-折叠分子的亲和力小于10 µM。
• Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders
  申请人：Deakin University

  公开号：US10568862B2

  公开（公告）日：2020-02-25

  The invention relates to a method of treatment and/or prophylaxis of a disease or disorder of the central nervous system comprising administering to a mammal in need thereof an effective amount of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract. The invention also relates to use of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, in the preparation of a medicament for the treatment and/or prophylaxis of a disease or disorder of the central nervous system and to a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, for use in the treatment and/or prophylaxis of a disease or disorder of the central nervous system.

  本发明涉及一种治疗和/或预防中枢神经系统疾病或紊乱的方法，包括向需要的哺乳动物施用有效量的富含黄酮的植物提取物或从富含黄酮的植物提取物衍生的化合物。 本发明还涉及富含黄酮的植物提取物或由富含黄酮的植物提取物衍生的化合物在制备治疗和/或预防中枢神经系统疾病或紊乱的药物中的用途，以及富含黄酮的植物提取物或由富含黄酮的植物提取物衍生的化合物在治疗和/或预防中枢神经系统疾病或紊乱中的用途。
• XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS
  申请人：DEAKIN UNIVERSITY

  公开号：EP3110414B1

  公开（公告）日：2020-09-30
• A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3860643A1

  公开（公告）日：2021-08-11
• [EN] XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS<br/>[FR] EXTRAITS DE PLANTE RICHES EN XANTHONE OU COMPOSÉS DÉRIVÉS DE CEUX-CI POUR LA MODULATION DE MALADIES DU SYSTÈME NERVEUX CENTRAL ET DE TROUBLES ASSOCIÉS
  申请人：UNIV DEAKIN

  公开号：WO2015127512A1

  公开（公告）日：2015-09-03

  The invention relates to a method of treatment and/or prophylaxis of a disease or disorder of the central nervous system comprising administering to a mammal in need thereof an effective amount of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract. The invention also relates to use of a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, in the preparation of a medicament for the treatment and/or prophylaxis of a disease or disorder of the central nervous system and to a xanthone-rich plant extract, or a compound derived from a xanthone-rich plant extract, for use in the treatment and/or prophylaxis of a disease or disorder of the central nervous system.